Full text is available at the source.
Abstract
Evidence supporting combined GLP-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease is limited.
- SGLT2 inhibitors are associated with reduced major kidney and cardiovascular events in chronic kidney disease patients.
- GLP-1 receptor agonists also demonstrate a similar reduction in major kidney and cardiovascular events.
- The effectiveness of combining both therapies in this population remains unclear and requires further investigation.
Simplified